|MDACC Study No:||2011-0253 (clinicaltrials.gov NCT No: NCT01398462)|
|Title:||A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia-2 (CMML-2), Myelodysplastic Syndrome Having Failed Hypomethylating Treatment (MDS), and High-Risk Myelofibrosis (MF)|
|Principal Investigator:||Jorge Cortes|
|Study Description:||The goal of this clinical research study is to learn the highest tolerable dose |
of the drug CWP232291 that can be given to patients with relapsed or refractory
AML CMML-2, MDS, or MF disease. The safety of CWP232291 will also be studied to
understand the best way to give the drug and also see what the best dose will
be for patients with hematologic disease.
CWP232291 is designed to target and block the function of messenger molecules
in cancer cells. This may slow the growth of tumors or kill the cancer cells.
This is the first study using CWP232291 in humans.